138530-95-7

Basic information

• Product Name: (S)-Lansoprazole
• Synonyms: (S)-Lansoprazole;1H-Benzimidazole, 2-[(S)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI);1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-, (S)-;Levolansoprazole;2-[(S)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole;2-[(S)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-;Lansoprazole S-IsoMer;(S)-2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
• CAS NO: 138530-95-7
• Molecular Formula: C₁₆H₁₄F₃N₃O₂S
• Molecular Weight: 369.3614696
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 138530-95-7.mol
• Article Data: 26

Chemical Properties

• Melting Point: 60-65°C
• Boiling Point: 555.8°Cat760mmHg
• Flash Point: 289.9°C
• Appearance: /
• Density: 1.5g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.635
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 9.56±0.10(Predicted)
• CAS DataBase Reference: (S)-Lansoprazole(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-Lansoprazole(138530-95-7)
• EPA Substance Registry System: (S)-Lansoprazole(138530-95-7)

Safety Data

• Hazardous Substances Data: 138530-95-7(Hazardous Substances Data)

Usage

Description

(S)-Lansoprazole is a proton pump inhibitor that irreversibly inhibits H+/K+-stimulated ATPase pumps in parietal cells (IC50 = 5.2 μM), inhibiting gastric acid secretion and increasing intragastric pH. It also inhibits acid formation in isolated canine parietal cells (IC50 = 82 μM). (S)-Lansoprazole is an enantiomerically pure form of lansoprazole . Both (S)- and (R)-lansoprazole are pharmacologically active with similar potencies.

Chemical Properties

Light Brown Solid

Uses

Different sources of media describe the Uses of 138530-95-7 differently. You can refer to the following data:
1. The S-enantiomer of Lansoprazole; a gastric proton pump inhibitor. An antiulcerative.
2. The S-enantiomer of Lansoprazole; a gastric proton pump inhibitor. An antiulcerative

InChI:InChI=1/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m0/s1

Upstream product

• 142384-07-4 (S)-(-)-2-(3-methyl-4-nitropyridin-2-ylmethansulfinyl)-1H-benzimidazole 
• 75-89-8 2,2,2-trifluoroethanol 
• 103577-45-3 lansoprasole 
• 1240684-31-4 C₂₆H₂₈F₃N₃O₅S₂ 
• 103577-40-8 lansoprazole sulfide 
• 134469-07-1 Benzimidazol-2-thiol 

Downstream Products

• 503833-45-2 isopropyl 1-[(S)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazol-l-yl] ethyl carbonate 

Relevant articles and documents

Method for preparing dexlansoprazole through catalysis of hexadentate ligand

The invention belongs to the technical field of chemical engineering, and particularly provides a method for preparing dexlansoprazole through catalysis of a hexadentate ligand. Under the catalysis ofa complex formed by a Ti(O-iPr)4 catalyst and a self-made hexadentate ligand, lansoprazole thioether is subjected to asymmetric oxidation, and dextral lansoprazole is obtained. The hexadentate ligandused in the method is simple to prepare and high in yield, and the complex formed by the hexadentate ligand and the Ti(O-iPr)4 catalyst is high in catalytic efficiency and high in enantiomeric excessvalue.

Preparation of asymmetric phase-transfer catalyst, 1,4-bis((4s,5s)-1,3-bis(3,5-di-tert-butylbenzyl)-4,5-diphenylimidazolidin-2-ylidene)piperazine-1,4-diium chloride

-

Enantioselective Separation over a Chiral Biphenol-Based Metal-Organic Framework

A chiral porous 3D metal-organic framework (MOF) is constructed from an enantiopure carboxylate ligand of 1,1′-biphenol, which can be utilized as adsorbent for the separation of aromatic alcohols and sulfoxides with enantioselectivity of up to 99.4%. Single-crystal X-ray diffraction analysis reveals the binding sites and host-guest interactions clearly, providing microscopic insight into the origin of the enantiosorption in the framework.